BMRN

Business Context and Reporting Period

Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: BioMarin is a global rare disease biotechnology company focused on genetically defined conditions. The company operates as a single business segment, managing a portfolio of commercial therapies and a clinical pipeline. As of April 23, 2026, there were 193,284,438 shares of common stock outstanding.

Key Financial Metrics

Note: All figures are in millions unless otherwise noted. Q1 2026 Net Income decreased primarily due to higher operating expenses and interest costs, despite revenue growth.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 2.8% to $766.2 million, driven by higher sales volumes of VIMIZIM, NAGLAZYME, BRINEURA, and VOXZOGO. This was partially offset by declines in ALDURAZYME and ROCTAVIAN (voluntarily withdrawn from the market in Q1 2026).
• Margin Compression: Gross margin decreased 5.2 percentage points to 74.5%. This was primarily due to a $31.0 million charge related to an unsuccessful process qualification campaign for NAGLAZYME manufacturing expansion.
• Expense Increases:
  • R&D: Increased 12.7% to $178.8 million, driven by higher spend on the later-stage clinical program BMN 401.
  • SG&A: Increased 25.3% to $258.3 million, due to global expansion of Enzyme Therapies and VOXZOGO, plus pre-close costs for the Amicus acquisition.
  • Interest Expense: Surged 424% to $15.0 million due to the issuance of $850 million in 5.5% senior notes in February 2026 and bridge commitment fees.
• Liquidity & Debt: Cash and cash equivalents increased significantly to $2.2 billion, bolstered by the issuance of $850 million in 2034 Notes (held in escrow) and the liquidation of investments to fund the upcoming Amicus acquisition. Long-term debt net increased to $1.43 billion.

Guidance, Outlook, and Risks

Recent Developments & Outlook

• Amicus Acquisition: On April 27, 2026 (subsequent to the reporting period), BioMarin completed the acquisition of Amicus Therapeutics for approximately $4.8 billion in equity value. This adds GALAFOLD and POMBILITI + OPFOLDA to the portfolio. The acquisition was financed via cash on hand, the 2034 Notes, and new senior secured term loans ($2.8 billion) and a revolving credit facility ($600 million).
• Product Pipeline:
  • Submitted a U.S. sNDA for full approval of VOXZOGO for achondroplasia.
  • Enrolled the first patient in the Phase 2/3 study of BMN 333 (long-acting CNP for achondroplasia).
  • Discontinued dosing in Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency, and ACAN-deficiency.
• Financial Outlook: Management expects Total Revenues to increase over the next 12 months following the Amicus acquisition. However, Interest Expense is expected to significantly increase due to the new debt load. Intangible asset amortization is also expected to rise significantly post-acquisition.

Risks and Contingencies

• Acquisition Integration: Risks include failure to realize anticipated benefits, integration difficulties, and potential unknown liabilities from Amicus.
• Regulatory & Legal: Ongoing DOJ investigation regarding sponsored testing programs for VIMIZIM and NAGLAZYME. Potential impact of government price controls (Inflation Reduction Act) and changes in orphan drug exclusivity rules in the EU.
• Debt Service: Increased indebtedness (totaling approx. $4.3 billion post-acquisition) creates significant fixed interest obligations and covenants that restrict financial flexibility.
• Manufacturing: Risks related to supply chain disruptions, single-source suppliers, and compliance with cGMP regulations.

Investor Verification Checklist

• Amicus Integration: Verify the timeline and financial impact of integrating Amicus Therapeutics, including the realization of cost synergies and revenue accretion.
• Debt Covenants: Review the specific financial covenants in the new 2026 Credit Agreement and the 2034 Notes indenture to assess leverage constraints.
• VOXZOGO Full Approval: Monitor the FDA's decision on the supplemental New Drug Application (sNDA) for full approval of VOXZOGO, which is critical for long-term growth.
• DOJ Investigation: Track the status of the Department of Justice investigation into sponsored testing programs for VIMIZIM and NAGLAZYME.
• Manufacturing Costs: Assess the long-term impact of the $31 million NAGLAZYME process qualification charge on future gross margins and production capacity.